Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

U.S. court denies Allergan bid to speed insider trading suit

Published 08/21/2014, 08:37 PM
Updated 08/21/2014, 08:37 PM
© Reuters Allergan CEO Pyott speaks during an interview in New York

(Reuters) - A federal judge in California on Thursday denied a request by Allergan Inc to expedite its civil suit claiming that Valeant Pharmaceuticals International Inc and Pershing Square Capital Management engaged in insider trading ahead of their bid to buy Allergan.

Judge David Carter said the U.S. District Court for the Central District of California "would be reluctant to create a precedent that allows corporations to demand at will the immediate attention and input of the federal courts in order to resolve intra-corporate disputes that might be better left to the dynamic free market or to the state court."

Valeant and Pershing Square made an offer for Botox maker Allergan in April, which the company has rejected. Valeant and Pershing Square have since proceeded to a hostile tender offer and are seeking to call a special shareholders meeting.

Allergan has fought the takeover attempt and on Aug. 1 filed a civil insider trading lawsuit against the companies, saying that the unusual partnership between them violated securities regulations.

William Ackman, the activist investor who runs Pershing Square, began acquiring a stake in Allergan in February in partnership with Valeant after the two had begun discussing making a bid for the company. He disclosed the nearly 10 percent stake the day before they made the offer.

Ackman and Valeant have denied that they broke insider trading laws and have said the suit itself is an attempt to delay the meeting of shareholders. Ackman and Valeant must gather the support of at least 25 percent of shareholders in order to call the meeting for investors to vote on new board members and on Allergan opening merger discussions.

"We are pleased that this attempt by Allergan in the California litigation to delay the special meeting was not successful," Valeant said in statement on Thursday.

© Reuters. Allergan CEO Pyott speaks during an interview in New York

Allergan, in a separate statement, said it intends to proceed along the path outlined by the court for a quick resolution once Pershing Square delivers requests for the special meeting.

(Reporting by Caroline Humer and Deena Beasley; Editing by Leslie Adler)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.